Overview

Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk

Status:
Unknown status

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy (and safety) of the following treatment squeme:Ciclophosphamide, Vincristine, lyposomal Doxorrubicine (Myocet) and Prednisone,combined with Rituximab in first line treatment for patients with aggresive No Hodgkin B lymphoma and cardiovascular risk

Phase:

Phase 2

Details

Lead Sponsor:

Asociacion Doctor Peset Para el Estudio de la Hematología

Collaborators:

Cephalon
Pivotal S.L.

Treatments:

Prednisone
Rituximab
Vincristine